Shunji Haruta
Director Técnico/Científico/I+D en SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. .
Cargos activos de Shunji Haruta
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Director Técnico/Científico/I+D | 01/01/2011 | - |
| SATSUMA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 08/06/2023 | - |
Historial de carrera de Shunji Haruta
Estadísticas
Internacional
| Japón | 2 |
| Estados Unidos | 2 |
Operativa
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectorial
| Commercial Services | 2 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
| Empresas privadas | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Bolsa de valores
- Insiders
- Shunji Haruta
- Experiencia
